LifeMD Inc(LFMD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.52 | Insider Own | 18.73% | Shs Outstand | 47.8M | Perf Week | -7.56% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | 82.37% | Insider Trans | - | Shs Float | 39.2M | Perf Month | -29.97% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.14 | Inst Own | 53.28% | Short Float | 19.29% | Perf Quarter | -45.83% |
| Income | -0.02B | P/S | 0.49 | EPS this Y | -307.43% | Inst Trans | 9.79% | Short Ratio | 8.98 | Perf Half Y | -54.49% |
| Sales | 0.20B | P/B | 12.49 | EPS next 5Y | -15.28% | ROA | -31.25% | Short Interest | 7.56M | Perf YTD | -39% |
| Book/sh | 0.17 | P/C | 3.99 | EPS past 3/5Y | 47.57% 44.86% | ROE | -674.34% | 52W High | -67.68% ($6.43) | Perf Year | -66.98% |
| Cash/sh | 0.52 | P/FCF | - | Sales past 3/5Y | 17.69% 39.08% | ROIC | -160.04% | 52W Low | -0.95% ($2.10) | Perf 3Y | -67.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -143.95% | Gross Margin | 82.43% | Volatility(W/M) | 5.21% 5.42% | Perf 5Y | -57.98% |
| Dividend TTM | - | EV/Sales | 0.4 | Sales Y/Y TTM | -16.73% | Oper. Margin | -9.35% | ATR (14) | 0.14 | Perf 10Y | 45.8% |
| Dividend Ex-Date | - | Quick Ratio | 0.84 | EPS Q/Q | -156.23% | Profit Margin | -11.92% | RSI (14) | 22.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.9 | Sales Q/Q | -24.01% | SMA20 | -16.96% ($2.5) | Beta | 2.19 | Target Price | $8.12 |
| Payout | - | Debt/Eq | 0.76 | Earnings | 2026/11/9 | SMA50 | -28.31% ($2.9) | Rel Volume | 0.43 | Prev Close | $2.13 |
| Employees | 389 | LT Debt/Eq | 0.67 | EPS/Sales Surpr. | -9.81% -3.78% | SMA200 | -43.76% ($3.7) | Avg Volume(3M) | 0.84M | Price | $2.08 |
| IPO | 2003/10/21 | Option/Short | Yes/Yes | Trades | 2053 | Volume | 361,136 | Change | -2.35% |
LifeMD is a US-based direct-to-consumer telehealth company. It has positioned weight management (anti-obesity medications) as its core growth driver and operates a digital healthcare platform that is expanding its care categories to include men's health, women's health, and behavioral health. The company is known for its integrated model that combines subscription-based virtual consultations with prescription and medication delivery services.
Over the past 1 year, on the lower side
68% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
Next earnings report: November 9
13 days to go.
LFMD has weak earning power
Of every $100 in sales, $9.35 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -307.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $49. Peers typically go for $70. Compared with its own 2-year average, it is 66% cheaper now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -58.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 53.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #30 of 41 in the industry
Based on market cap of $100M.
FAQ
What kind of company is LFMD?
LFMD belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of LFMD?
The market cap of LFMD is approximately $100M, ranking 4,475 within its sector.
What is the 52-week high and low for LFMD?
LFMD has recorded a 52-week high of $6.43 and a low of $2.10.
